Class II — Potential Health Hazard

Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

FAMOTIDINE Tablet Recalled by Aidapak Services, LLC Due to Mislabeling

Date: July 2, 2013
Company: Aidapak Services, LLC
Status: Terminated
Source: FDA (Drug)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Aidapak Services, LLC directly.

Affected Products

FAMOTIDINE Tablet, 20 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 16714036104

Quantity: 700 Tablets

Why Was This Recalled?

Labeling: Label Mixup; FAMOTIDINE Tablet, 20 mg may be potentially mislabeled as CARVEDILOL PHOSPHATE ER, Capsule, 20 mg, NDC 00007337113, Pedigree: W003225, EXP: 6/17/2014; DULoxetine HCl DR, Capsule, 20 mg, NDC 00002323560, Pedigree: W003506, EXP: 6/21/2014; FAMOTIDINE, Tablet, 20 mg, NDC 16714036104, Pedigree: W003507, EXP: 6/21/2014; MYCOPHENOLATE MOFETIL, Capsule, 250 mg, NDC 0037822500

Where Was This Sold?

Repacked drugs were distributed in Arizona, California, Oregon, and Washington.

About Aidapak Services, LLC

Aidapak Services, LLC has 538 total recalls tracked by RecallDetector.

Related Recalls

Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...

Zydus Pharmaceuticals (USA) Inc · March 9, 2026

Class II — Potential Health Hazard

Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...

Rising Pharma Holding, Inc. · March 3, 2026

Class II — Potential Health Hazard

Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility

New Life Pharma LLC · February 26, 2026

Class II — Potential Health Hazard

Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility

New Life Pharma LLC · February 26, 2026

Class II — Potential Health Hazard

Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility

New Life Pharma LLC · February 26, 2026

Class II — Potential Health Hazard

Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report